Home > Insider Trading > Filing (0001654954-21-001750)

Filing Details

Accession Number:: 0001654954-21-001750
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-16 19:35:11
Reporting Period:: 2021-02-11

Accepted Time:: 2021-02-16 19:35:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1645469	Monopar Therapeutics	MNPR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1035909	J Michael Brown	C/O 1000 Skokie Blvd Ste 350 Wilmette IL 60091		No	No	No	No
1727334	Chandler Robinson	C/O 1000 Skokie Blvd, Ste 350 Wilmette IL 60091	Chief Executive Officer	No	No	No	No
1727357	Tactic Pharma Llc	C/O 1000 Skokie Blvd, Ste 350 Wilmette IL 60091		No	No	No	No
1727393	Paul Andrew Mazar	C/O 1000 Skokie Blvd, Ste 350 Wilmette IL 60091	Chief Scientific Officer	No	No	No	No
1727481	V. Thomas O'halloran	C/O 1000 Skokie Blvd, Ste 350 Wilmette IL 60091		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-02-11	42,467	$13.30	249,200	No	4	S	Direct
Common Stock	Disposition	2021-02-11	24,224	$14.09	224,976	No	4	S	Direct
Common Stock	Disposition	2021-02-11	29,996	$15.12	194,980	No	4	S	Direct
Common Stock	Disposition	2021-02-11	16,384	$16.44	178,596	No	4	S	Direct
Common Stock	Disposition	2021-02-11	11,929	$16.90	166,667	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,111,273	Indirect	See Footnotes

Footnotes

Trade made pursuant to a 10b5-1 plan executed on November 24, 2020.
This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. Thereporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive.
Tactic shares voting and investment power over 4,111,272.88 of the shares of common stock held by TacticGem LLC.